Christopher Ballas, PhD

Christopher Ballas, PhD

Chris has over 20 years’ experience working on cell and gene therapies. He currently serves as SVP of Manufacturing at ICT and was previously VP of Manufacturing for Rocket Pharma, Sr. Director of Process Development and Commercialization for WuXi Apptec after having had responsibility there for Manufacturing Operations and Program Management for gene therapy clients. Chris was responsible for key programs including CAR-T, TIL, and classic CD34+ stem cell gene therapy. Prior to that Chris was responsible for running autologous cell therapy clinical trials for Cook Medical which included several different indications and studies from feasibility through Phase III/pivotal. Before Cook, Chris was at the Indiana University School of Medicine in several roles, including management of process development and clinical production capabilities at the IU Vector Production Facility. He also served as faculty with his own research programs on targeting of stem cells for gene therapy which resulted in issued (US9885059) and applied patents and spinout of Basilard BioTech from the University of California Riverside. Chris has served as an expert consultant to numerous companies on gene therapy and the production and use of viral vectors for gene therapies.

Chris has a Ph.D. in Cellular and Molecular Pathology from Vanderbilt University School of Medicine and was a Children’s Brittle Bone Foundation Fellow during his post-doctoral fellowship at Case Western Reserve University School of Medicine. He has a passion for driving gene therapy forward by solving the practical challenges associated with producing and using viral vectors to treat genetic diseases.